You are here
Award Data
The Award database is continually updated throughout the year. As a result, data for FY24 is not expected to be complete until March, 2025.
Download all SBIR.gov award data either with award abstracts (290MB)
or without award abstracts (65MB).
A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.
The SBIR.gov award data files now contain the required fields to calculate award timeliness for individual awards or for an agency or branch. Additional information on calculating award timeliness is available on the Data Resource Page.
-
Topical Treatment for Mild Psoriasis
SBC: APELIOTUS TECHNOLOGIES, INC. Topic: N/ADESCRIPTION (provided by applicant): This STTR Phase I proposal is directed at the development of a topical treatment for mild psoriasis. It is based on the recent discovery of a cell signaling module important for the regulation of keratinocyte proliferation and differentiation. This signaling module is centered on the enzyme phospholipase D2 (PLD2). PLD2 normally hydrolyzes cell membrane phospho ...
STTR Phase I 2007 Department of Health and Human ServicesNational Institutes of Health -
Neural cell based assays derived from human ES cells
SBC: ARUNA BIO, INC. Topic: N/ADESCRIPTION (provided by applicant): Neurons send instructions to other cells in the form of electrical signals that allow movement, sensation, memory, learning and countless other activities that are taken for granted in daily life. Loss of neural cell function results from traumatic injuries such as gunshots wounds or car accidents and from neurodegenerative diseases. The scale of this health p ...
STTR Phase I 2005 Department of Health and Human ServicesNational Institutes of Health -
Development of Software for Comparative/Quantitative Clinical Proteomics
SBC: BIOINQUIRE, LLC Topic: N/ADESCRIPTION (provided by applicant): There is currently a significant demand for proteomics software which enables rapid and accurate data analysis. The advances over recent years in proteomics instrumentation and throughput coupled with the continued expa nsion of biological databases has resulted is researchers being able to produce very large amounts of data in relatively short time periods. Si ...
STTR Phase I 2008 Department of Health and Human ServicesNational Institutes of Health -
Development of Software for Comparative/Quantitative Clinical Proteomics
SBC: BIOINQUIRE, LLC Topic: N/ADESCRIPTION (provided by applicant): There is currently a significant demand for proteomics software which enables rapid and accurate data analysis. The advances over recent years in proteomics instrumentation and throughput coupled with the continued expansion of biological databases has resulted is researchers being able to produce very large amounts of data in relatively short time periods. Sin ...
STTR Phase II 2009 Department of Health and Human ServicesNational Institutes of Health -
Development of Software to Annotate/Interpret MS data of O and N-linked Glycans
SBC: BIOINQUIRE, LLC Topic: N/ADESCRIPTION (provided by applicant): There is currently a significant demand for glycomic software which enables rapid and accurate data analysis. The advances over recent years in mass spectrometry instrumentation and throughput has resulted is researchers being able to produce very large amounts of data in relatively short time periods. Since informatics developments have not kept pace with the ...
STTR Phase I 2009 Department of Health and Human ServicesNational Institutes of Health -
N/A
SBC: Cell Separation Technologies Topic: N/AN/A
STTR Phase I 2000 Department of Health and Human ServicesNational Institutes of Health -
N/A
SBC: Computer Source Topic: N/AN/A
STTR Phase I 2000 Department of Health and Human ServicesNational Institutes of Health -
Developing Adjuvant SiRNA Therapy for Huntington's Disease
SBC: EFFIGENE PHARMACEUTICALS, INC. Topic: N/ADESCRIPTION (provided by applicant): SiRNAs are synthetic double-stranded oligonucleotides of ~21 base pairs. When applied to cells, siRNAs can effectively and specifically silence their target genes, called RNA interference (RNAi). RNAi has become attract ive tool for functional genomics and a potential class of molecules for human therapeutics. However, almost every siRNA drug company encounters ...
STTR Phase I 2008 Department of Health and Human ServicesNational Institutes of Health -
Developing Small Molecules to Potentiate RNA Interference
SBC: EFFIGENE PHARMACEUTICALS, INC. Topic: N/ADESCRIPTION (provided by applicant): SiRNAs are synthetic double-stranded oligonucleotides of ~21 base pairs. When applied to cells, siRNAs can effectively and specifically silence their target genes, called RNA interference (RNAi). RNAi has become attractive tool for functional genomics and a potential class of molecules for human therapeutics. However, almost every siRNA drug company encounters ...
STTR Phase I 2009 Department of Health and Human ServicesNational Institutes of Health -
Ex Vivo Gene Therapy of Hemophilia A
SBC: EXPRESSION THERAPEUTICS, LLC Topic: N/ADESCRIPTION (provided by applicant): Hemophilia A is a bleeding disorder caused by mutations within the factor VIII (fVIII) gene that result in a deficiency of circulating fVIII activity. Current treatment for hemophilia relies on infusion of plasma-derived or recombinant fVIII to restore circulating fVIII activity. This form of therapy is 1) expensive, 2) hard to maintain due to the frequency and ...
STTR Phase I 2006 Department of Health and Human ServicesNational Institutes of Health
